As of 2026-08-28, RIGEL PHARMACEUTICALS INC (RIGL) trades at $46.86 against an EvidInvest fair-value range of $27.31–$305 (base estimate $80.27), built from 6 independent valuation methods on filed financial statements. The market price is 42% below the base estimate, so the models read the stock as fairly valued. Research, not investment advice.
Download the full RIGL valuation report (PDF) — free
DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.
Interpretation
PEG = P/E ÷ Annual EPS Growth Rate (%). Peter Lynch's growth-adjusted value metric.
Interpretation
EV/EBITDA = Enterprise Value ÷ EBITDA. Capital-structure neutral — preferred by professional investors.
Interpretation
P/S = Market Cap ÷ Revenue. Useful for growth/unprofitable companies. SaaS/high-growth norms higher.
Interpretation
P/B = Price ÷ Book Value per Share. Essential for banks, REITs, and asset-heavy companies.
52.4% discount vs current price
Interpretation
√(22.5 × EPS × Book Value/Share) — Benjamin Graham's intrinsic value estimate.
-160.7% vs current price ($46.86)
TTM EBIT deviates 191% from 3-year average. Using normalized EBIT ($43M) for stability.
🔴 Destroying value
Greenwald EPV assumes zero future growth — this is the floor value of the business as a going concern.